NASDAQ · PHIO

Phio Pharmaceuticals Corp.

Closing price · Nov 13, 2026 $0.771

Last insider buy price $0.84 Paid by Director David Deming on Nov 11, 2026 (Form 4). Not today's price.

Latest quarter · ended Sep 30, 2026

Cash got weaker

descriptionFiled Nov 5, 2026

Cash from operationsWorse

−$2.28M

Dec '24Sep '26

vs. −$2.08M a year ago

Share countDiluting

+11.0%

Dec '24Sep '26

11.95M shares vs. 10.76M a year ago

Numbers come from the company's own 10-Q and 10-K reports filed with the SEC. Each bar is one quarter, oldest on the left. The colored bar is the latest. Hover over or tap a bar to see its number.

Smart money pulse

What insiders and funds are doing

Buying Insiders: as of Nov 13 Funds: as of Jun 30, 2026

group
3 insiders bought in the last 30 days. $45.8K in open-market buys, Nov 9–11.
info
No real insider sales in 12 months. Planned 10b5-1 sales and tax withholding are left out.

−100 means everyone selling, +100 everyone buying. This is data, not advice.

How the Pulse works

Pulse runs from −100 (everyone selling) to +100 (everyone buying). Half comes from insiders: real buyers vs. real sellers in the last 90 days (Form 4). Half comes from funds: funds that bought vs. funds that sold last quarter (13F). 13F is a snapshot of long positions on the last day of the quarter, filed up to 45 days later. It does not show short positions or trades since then.

Who owns it

24 funds report owning PHIO, same as the quarter before

Holdings as of Jun 30, 2026

New4

Added5

Held9

Trimmed6

Sold out4

Insider trades · last 12 months

Real buys and sales

● Open-market buy● Open-market sale

Last 6 months. A wider screen shows 12.

Showing 14 real trades. Hidden: 9 stock grants, 2 tax withholdings. Those happen on a schedule and say little about what an insider thinks. Bigger dot means a bigger trade.

Real trades, newest first

Nov 11 David Deming Director Open-market buy $4.36K 5,200 sh at $0.84

Nov 10 David Deming Director Open-market buy $5.71K 6,800 sh at $0.84

Nov 9 Robert Bitterman Chairman, Pres. & CEO, Director Open-market buy $20.5K 25,000 sh at $0.82

Nov 9 Ronald Plott Director Open-market buy $15.2K 18,300 sh at $0.83

Sep 29 Ronald Plott Director Open-market buy $5.2K 5,000 sh at $1.04

Sep 28 Ronald Plott Director Open-market buy $5.15K 5,000 sh at $1.03

Sep 24 Patricia Bradford Director Open-market buy $6.57K 6,500 sh at $1.01

Sep 22 Robert Bitterman Chairman, Pres. & CEO, Director Open-market buy $2.06K 2,000 sh at $1.03

Sep 15 Patricia Bradford Director Open-market buy $12.4K 12,000 sh at $1.03

Aug 19 Ronald Plott Director Open-market buy $17.1K 15,000 sh at $1.14

Show 4 older real trades

Aug 18 Robert Bitterman Chairman, Pres. & CEO, Director Open-market buy $10.6K 10,000 sh at $1.06

Jun 26 Robert Bitterman Chairman, Pres. & CEO, Director Open-market buy $9.9K 10,000 sh at $0.99

Dec 31 Robert Bitterman Chairman, Pres. & CEO, Director Open-market buy $5.15K 5,000 sh at $1.03

Dec 23 Robert Bitterman Chairman, Pres. & CEO, Director Open-market buy $5.1K 5,000 sh at $1.02

Showing every filing. Dashed circles are routine: grants, tax withholding, option exercises and planned sales.

Top holders

Biggest funds in PHIO

As of Jun 30, 2026

Fund	Owns	Value	Change
Jane Street Group, LLC	1.0%	$121K	−1%
Geode Capital Management, LLC	1.0%	$117K	−22%
Vanguard Capital Management LLC	0.8%	$96.6K	+18%
Nomura Asset Management International Inc.	0.4%	$51K	New
Cetera Investment Advisers	0.4%	$48.7K	+6%

"Owns" is shares reported divided by shares outstanding.